Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

Med J Aust. 2021 Oct 7. doi: 10.5694/mja2.51303. Online ahead of print.NO ABSTRACTPMID:34622467 | DOI:10.5694/mja2.51303

Source: Medical Journal of Australia - October 8, 2021 Category: General Medicine Authors: Ashish Srinivasan Craig Haifer Lena Thin Source Type: research